First Reported Case of Anaphylaxis to Nebulized Tranexamic Acid in a Pediatric Patient: A Rare but Critical Event.

IF 1.1 4区医学 Q4 ALLERGY

Pediatric Allergy Immunology and Pulmonology Pub Date : 2024-07-31 DOI:10.1089/ped.2024.0035

Doğukan Mustafa Keskin, Mehmet Kocaoğlu, Alper Yıldırım, Ender Sayan, Muhammed Yusuf Ozan Avcı

{"title":"First Reported Case of Anaphylaxis to Nebulized Tranexamic Acid in a Pediatric Patient: A Rare but Critical Event.","authors":"Doğukan Mustafa Keskin, Mehmet Kocaoğlu, Alper Yıldırım, Ender Sayan, Muhammed Yusuf Ozan Avcı","doi":"10.1089/ped.2024.0035","DOIUrl":null,"url":null,"abstract":"Background: Tranexamic acid (TXA) is a medication used to treat or prevent excessive blood loss due to certain medical conditions. It has a low side effect profile and is safe to administer in most instances. Anaphylaxis cases due to intravenous TXA have been reported in the literature. We report the first pediatric case of anaphylaxis due to the use of nebulized TXA. Case Presentation: A 2-year-old boy with cerebral palsy, epilepsy, and tracheostomy was hospitalized with pneumonia. On the fourth day of hospitalization, the patient started bleeding from the trachea. Nebulized TXA was started to reduce tracheal bleeding. Anaphylaxis developed 5 min after administration of nebulized TXA. Subsequently, the patient was successfully treated with adrenaline, intravenous fluids, antihistamines, and steroids. Conclusion: Nebulized TXA is increasingly used off-label. Although it has a safe profile, side effects such as anaphylaxis may occur rarely. It is essential to recognize the symptoms of anaphylaxis when using nebulized TXA.","PeriodicalId":54389,"journal":{"name":"Pediatric Allergy Immunology and Pulmonology","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Allergy Immunology and Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ped.2024.0035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tranexamic acid (TXA) is a medication used to treat or prevent excessive blood loss due to certain medical conditions. It has a low side effect profile and is safe to administer in most instances. Anaphylaxis cases due to intravenous TXA have been reported in the literature. We report the first pediatric case of anaphylaxis due to the use of nebulized TXA. Case Presentation: A 2-year-old boy with cerebral palsy, epilepsy, and tracheostomy was hospitalized with pneumonia. On the fourth day of hospitalization, the patient started bleeding from the trachea. Nebulized TXA was started to reduce tracheal bleeding. Anaphylaxis developed 5 min after administration of nebulized TXA. Subsequently, the patient was successfully treated with adrenaline, intravenous fluids, antihistamines, and steroids. Conclusion: Nebulized TXA is increasingly used off-label. Although it has a safe profile, side effects such as anaphylaxis may occur rarely. It is essential to recognize the symptoms of anaphylaxis when using nebulized TXA.

查看原文本刊更多论文

首例报告的小儿雾化氨甲环酸过敏性休克病例：罕见但危急的事件

背景：氨甲环酸（TXA氨甲环酸（TXA）是一种药物，用于治疗或预防某些疾病导致的失血过多。它的副作用较小，在大多数情况下用药安全。静脉注射 TXA 引起过敏性休克的病例已有文献报道。我们报告了首例因使用雾化 TXA 而导致过敏性休克的儿科病例。病例介绍：一名患有脑瘫、癫痫和气管切开术的 2 岁男孩因肺炎住院。住院第四天，患者气管开始出血。为减少气管出血，患者开始使用雾化 TXA。雾化 TXA 使用 5 分钟后出现过敏性休克。随后，患者成功接受了肾上腺素、静脉输液、抗组胺药和类固醇治疗。结论雾化 TXA 越来越多地被用于标签外。虽然它的安全性很高，但过敏性休克等副作用可能很少发生。在使用雾化 TXA 时，必须识别过敏性休克的症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Allergy Immunology and Pulmonology ALLERGY-IMMUNOLOGY

CiteScore

2.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Pediatric Allergy, Immunology, and Pulmonology is a peer-reviewed journal designed to promote understanding and advance the treatment of respiratory, allergic, and immunologic diseases in children. The Journal delivers original translational, clinical, and epidemiologic research on the most common chronic illnesses of children—asthma and allergies—as well as many less common and rare diseases. It emphasizes the developmental implications of the morphological, physiological, pharmacological, and sociological components of these problems, as well as the impact of disease processes on families. Pediatric Allergy, Immunology, and Pulmonology coverage includes: -Functional and genetic immune deficiencies- Interstitial lung diseases- Both common and rare respiratory, allergic, and immunologic diseases- Patient care- Patient education research- Public health policy- International health studies